Onconetix, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ONCO Nasdaq 2830 www.onconetix.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Onconetix, Inc.

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series - Aug 6th, 2026 6:30 am
Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG - Aug 5th, 2026 6:30 am
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation - Jul 7th, 2026 7:00 am
Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District - Jun 24th, 2026 6:30 am
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split - May 19th, 2026 6:00 am
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study - May 13th, 2026 7:25 am
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development - Apr 17th, 2026 5:00 pm
Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson - Apr 9th, 2026 6:30 am
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy - Apr 7th, 2026 4:00 pm
Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update - Apr 2nd, 2026 6:30 am
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors - Mar 31st, 2026 6:30 am
BC-Most Active Stocks - Mar 27th, 2026 8:30 am
Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration - Mar 25th, 2026 10:47 am
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split - Mar 23rd, 2026 6:30 am
Realbotix Announces the Sale of Realbotix, LLC Subsidiary to Onconetix - Feb 12th, 2026 7:58 am
Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company - Feb 12th, 2026 6:00 am
Onconetix announces financing through private placement, debt settlement - Sep 27th, 2025 6:40 am
Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. - Sep 26th, 2025 6:30 am
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement - Sep 26th, 2025 6:15 am
Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM - Sep 22nd, 2025 6:00 am